<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04817501</url>
  </required_header>
  <id_info>
    <org_study_id>CTC Phenotyping</org_study_id>
    <nct_id>NCT04817501</nct_id>
  </id_info>
  <brief_title>Phenotypic Spectrum of CTCs in Tumors of the Female Reproductive System</brief_title>
  <acronym>CTCs</acronym>
  <official_title>Phenotypic Spectrum of Circulating Tumor Cell Populations as Markers of Liquid Biopsy in Tumors of the Female Reproductive System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tomsk National Research Medical Center of the Russian Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tomsk National Research Medical Center of the Russian Academy of Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates the level and molecular profiles of different CTC populations as markers&#xD;
      for predicting the risk of developing hematogenous metastases and the effectiveness of&#xD;
      treatment in patients with tumors of the female reproductive system (breast cancer,&#xD;
      endometrial cancer, and ovarian cancer).&#xD;
&#xD;
      The primary objective are:&#xD;
&#xD;
        1. To assess the presence and number of different populations of CTCs at different time&#xD;
           points (before biopsy, before surgery, and after surgery).&#xD;
&#xD;
        2. To assess the relationships of different CTCs populations prior to treatment initiation&#xD;
           with the effects of neoadjuvant chemotherapy and the risks of recurrence and metastases.&#xD;
&#xD;
        3. To assess the molecular profiles of different CTCs populations in the blood and in&#xD;
           ascitic fluid.&#xD;
&#xD;
      The secondary objective is to compare the multicolor flow cytometry results with data of&#xD;
      ultrasound, CT and/or MRI, serum tumor markers, and immunohistochemical studies in patients&#xD;
      with breast cancer, endometrial cancer and ovarian cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall goal is to study the diagnostic and prognostic efficacy of various CTC&#xD;
      populations as liquid biopsy markers in tumors of the female reproductive system (breast&#xD;
      cancer, endometrial cancer, and ovarian cancer).&#xD;
&#xD;
      Phase I study:&#xD;
&#xD;
      Determination of different populations of CTCs in blood and ascitic fluid (if any) prior to&#xD;
      treatment.&#xD;
&#xD;
      The main objectives of the study:&#xD;
&#xD;
        1. To assess the presence and number of different CTC populations at different time points&#xD;
           (before biopsy and before surgery) using multicolor flow cytometry.&#xD;
&#xD;
        2. To assess the relationships between different CTCs populations prior to treatment&#xD;
           initiation with the effects of neoadjuvant chemotherapy and the risks of recurrence and&#xD;
           metastases.&#xD;
&#xD;
        3. To assess the molecular profiles of different CTCs populations in the blood and in&#xD;
           ascitic fluid.&#xD;
&#xD;
      Additional research tasks:&#xD;
&#xD;
      To compare the multicolor flow cytometry results with the data of ultrasound, CT and/or MRI,&#xD;
      serum tumor markers, and immunohistochemical studies in patients with breast cancer,&#xD;
      endometrial cancer, and ovarian cancer Methodology: Open-label, exploratory, single centre&#xD;
      study. Blood and ascitic fluid collected from subjects (if available)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 14, 2014</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>CTC phenotype</measure>
    <time_frame>6 hours</time_frame>
    <description>Different populations of CTCs are evaluated by multicolor flow cytometry and may include:&#xD;
СTC, ascitic tumor cells with stemness features without EMT features; CTC, ascitic tumor cells without stemness and EMT features; CTC, ascitic tumor cells without stemness features and with EMT features; CTC, ascitic tumor cells with stemness features and EMT features; Atypical/hybrid cells without stemness features; Atypical cells.</description>
  </primary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>Breast cancer</arm_group_label>
    <description>At least eighty five subjects with breast cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ovarian cancer</arm_group_label>
    <description>At least 32 subjects with ovarian cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endometrial Cancer</arm_group_label>
    <description>At least 33 subjects with endometrial cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control</arm_group_label>
    <description>30 healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Suspected malignant tumor non-verified</arm_group_label>
    <description>Patients with suspected malignant tumor, which was not verified by biopsy. Nubmber of patients to be defined</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Taking 5 ml of venous blood at different time intervals</intervention_name>
    <arm_group_label>Breast cancer</arm_group_label>
    <arm_group_label>Endometrial Cancer</arm_group_label>
    <arm_group_label>Healthy control</arm_group_label>
    <arm_group_label>Ovarian cancer</arm_group_label>
    <arm_group_label>Suspected malignant tumor non-verified</arm_group_label>
    <other_name>Taking 5 ml EDTA-stabilized ascitic fluid sampled during laparoscopy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Taking 5 ml EDTA-stabilized ascitic fluid sampled during laparoscopy if any</intervention_name>
    <arm_group_label>Breast cancer</arm_group_label>
    <arm_group_label>Endometrial Cancer</arm_group_label>
    <arm_group_label>Ovarian cancer</arm_group_label>
    <arm_group_label>Suspected malignant tumor non-verified</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      EDTA-stabilized venous blood (5 mL) EDTA-stabilized ascitic fluid (5 mL)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Women over 18 years of age.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is &gt; 18 years of age A negative pregnancy test (serum beta-human chorionic&#xD;
             gonadotropin, beta-HCG) at screening for all patients of childbearing potential.&#xD;
&#xD;
          -  Clinical and radiological diagnosis of breast cancer or Ovarian cancer or Endometrial&#xD;
             Cancer General satisfactory condition (according to the ECOG scale ≤2) Subject is&#xD;
             capable to undergo the diagnostic investigations to be performed in the study&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active current autoimmune disease or history of autoimmune disease&#xD;
&#xD;
               -  Active infection or history of severe infection within the previous 3 months (if&#xD;
                  clinically relevant at screening)&#xD;
&#xD;
               -  Known HIV positive or chronically active hepatitis B or C The subject has&#xD;
                  multiple primary malignant tumors&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Gender Based: women for breast cancer, Ovarian cancer, Endometrial Cancer</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evgeniya Kaigorodova</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tomsk NRMC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Evgeniya Kaigorodova, MD,PhD</last_name>
    <phone>+7-3822-282686</phone>
    <email>zlobinae@mail.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nina Anfinogenova, MD,PhD</last_name>
    <phone>89095390220</phone>
    <email>anfiyj@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Evgeniya Kaigorodova</name>
      <address>
        <city>Tomsk</city>
        <state>Tomskaya Oblast</state>
        <zip>634050</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evgeniya Kaigorodova, MD,PhD</last_name>
      <phone>+7-3822-282686</phone>
      <email>zlobinae@mail.ru</email>
    </contact>
    <contact_backup>
      <last_name>Nina Anfinogenova, MD,PhD</last_name>
      <phone>89095390220</phone>
      <email>anfiyj@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 23, 2021</study_first_submitted>
  <study_first_submitted_qc>March 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2021</study_first_posted>
  <last_update_submitted>March 23, 2021</last_update_submitted>
  <last_update_submitted_qc>March 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>endometrial Cancer</keyword>
  <keyword>ovarian cancer</keyword>
  <keyword>CTC heterogeneity</keyword>
  <keyword>cancer stem cells</keyword>
  <keyword>epithelial-mesenchymal transition</keyword>
  <keyword>multicolor flow cytometry</keyword>
  <keyword>liquid biopsy</keyword>
  <keyword>circulating tumor cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Genital Neoplasms, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edetic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

